Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...
The properties of the different IgG isotypes should be considered in developing therapeutic antibodies. To address this problem, antibody engineers introduced a serine-to-proline substitution that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback